Lorcainide

Lorcainide

Clinical data
ATC code	C01BC07 (WHO)
Pharmacokinetic data
Protein binding	78
Elimination half-life	14.3 +/-3.7
Identifiers
IUPAC name N-(4-chlorophenyl)-N-(1-isopropylpiperidin-4-yl)-2-phenylacetamide
CAS Number	59729-31-6 N
PubChem CID	42884
ChemSpider	39116 Y
UNII	KGJ2T0N7IQ
KEGG	D08020 Y
ChEMBL	ChEMBL87543 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H27ClN2O
Molar mass	370.915 g/mol
3D model (JSmol)	Interactive image
SMILES Clc3ccc(N(C(=O)Cc1ccccc1)C2CCN(C(C)C)CC2)cc3
InChI InChI=1S/C22H27ClN2O/c1-17(2)24-14-12-21(13-15-24)25(20-10-8-19(23)9-11-20)22(26)16-18-6-4-3-5-7-18/h3-11,17,21H,12-16H2,1-2H3 Y Key:XHOJAWVAWFHGHL-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Lorcainide
Articles
Most recent articles on Lorcainide Most cited articles on Lorcainide Review articles on Lorcainide Articles on Lorcainide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Lorcainide Images of Lorcainide Photos of Lorcainide Podcasts & MP3s on Lorcainide Videos on Lorcainide
Evidence Based Medicine
Cochrane Collaboration on Lorcainide Bandolier on Lorcainide TRIP on Lorcainide
Clinical Trials
Ongoing Trials on Lorcainide at Clinical Trials.gov Trial results on Lorcainide Clinical Trials on Lorcainide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Lorcainide NICE Guidance on Lorcainide NHS PRODIGY Guidance FDA on Lorcainide CDC on Lorcainide
Books
Books on Lorcainide
News
Lorcainide in the news Be alerted to news on Lorcainide News trends on Lorcainide
Commentary
Blogs on Lorcainide
Definitions
Definitions of Lorcainide
Patient Resources / Community
Patient resources on Lorcainide Discussion groups on Lorcainide Patient Handouts on Lorcainide Directions to Hospitals Treating Lorcainide Risk calculators and risk factors for Lorcainide
Healthcare Provider Resources
Symptoms of Lorcainide Causes & Risk Factors for Lorcainide Diagnostic studies for Lorcainide Treatment of Lorcainide
Continuing Medical Education (CME)
CME Programs on Lorcainide
International
Lorcainide en Espanol Lorcainide en Francais
Business
Lorcainide in the Marketplace Patents on Lorcainide
Experimental / Informatics
List of terms related to Lorcainide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Lorcainide (Lorcainide hydrochloride) is a Class 1c antiarrhythmic agent that is used to help restore normal heart rhythm and conduction in patients with premature ventricular contractions, ventricular tachycardiac [7] and Wolff-Parkinson-White syndrome. [9] Lorcainide was developed by Janssen Pharmaceutica (Belgium) in 1968 under the commercial name Remivox and is designated by code numbers R-15889 or Ro 13-1042/001. [2] It has a half-life of 8.9 +- 2.3 hrs which may be prolonged to 66 hrs in people with cardiac disease [9].

Arrhythmia

Cardiac dysrhythmia is a heart rate disorder that manifests as an altered cardiac rhythm. It results from either abnormal pacemaker activity or a disturbance in impulse propagation, or both. [6] Arrhythmias can be caused by various conditions including ischemia, hypoxia, pH disruptions, B adrenergic activation, drug interactions or the presence of diseased tissue. [5] These events can trigger the development of ectopic pacemaker in the heart, which emit abnormal impulses at random times during the cardiac cycle. An arrhythmia can present itself as either bradycardia or tachycardia. [5] Untreated arrhythmias may progress to atrial fibrillation or ventricular fibrillation. [5] Treatment is aimed at normalizing cardiac rhythm by altering ion flow across the membrane. Antiarrhythmic agents can reduce arrhythmia related symptoms such as palpitations or syncope; however, they often have a narrow therapeutic index and can also be proarrhythmic[6].

Wolff-Parkinson-White syndrome

Wolff-Parkinson-White syndrome (WPW) is a pre-excitation syndrome in which individuals are predisposed to supraventricular tachyarrhythmias (rapid and irregular heart beats). [1] People with this condition have an extra or accessory atrioventricular conduction pathway that causes re-entry tachycardia. [1] WPW is characterized by a short PR interval (<0.12 second) and a prolonged, slurred QRS complex (>0.12 seconds). [1]

Class 1c activity

Fast-acting voltage-gated sodium channels (Nav1.5) found in high concentrations in the ventricular myocytes, open at a membrane potential of −80 mv in typical cardiac rhythm. This will result in a rapid upstroke of an action potential that leads to contraction of the ventricles.[8] Class 1c drugs have local anesthetic properties and have a high affinity for open Nav1.5 (but not closed or inactive Nav1.5), thus irreversibly binding and reducing the fast Na+ influx. Interactions of Lorcainide with Nav1.5 are time and voltage dependent. Class 1c drugs have a characteristically slow dissociation rate, which will slow the upstroke duration and amplitude of ventricular myocytes’ action potential and prolong the PR, QRS and QT intervals of an ECG.[4] Lorcainide also increases the ventricular fibrillation threshold in a dose-dependent fashion.[4] Overall, Lorcainide causes a decrease in tachycardiac events, but also reduced ventricular contractility ejection fraction. The effect on sinus node function is controversial, as some researchers have noted a decreased sinus cycle length and increase in sinus node recovery, whereas others have observed no change. [4]

Other Activities

Lorcainide inhibits adenosine 5’-triphosphate (ATP)-hydrolytic action of myocardial Na+K+ATPase in-vitro in a concentration dependent manner. The mode of action and the implications of this finding are not well known. [3]

Benefits And Risks

Lorcainide exhibits a prolonged duration of action (approximately 8-10 hrs), is well absorbed when taken orally and has a good safety profile as well as a good drug efficacy. [6] Hematologic, biochemical and urinary analysis of Lorcainide revealed no significant abnormalities. [9] However, an increased prevalence of central nervous system effects, including headache, dizziness and sleep disturbances have been associated with oral dosages of Lorcainide when compared to intravenous administration. This could be due to a greater accumulation of plasma Noriorcainide when exposed to oral Lorcainide. Noriorcainide, an N-dealkylated derivative, is an active metabolite of Lorcainide. It is as potent as its parent compound with similar antiarrhythmic efficacy, wherein it suppresses chronic premature ventricular complexes. [4] It has a half life of 26.5 +-7.2 hrs. [9]